Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
89.6M
-
Number of holders
-
153
-
Total 13F shares, excl. options
-
74.7M
-
Shares change
-
+10.8M
-
Total reported value, excl. options
-
$1.04B
-
Value change
-
+$151M
-
Put/Call ratio
-
0.96
-
Number of buys
-
102
-
Number of sells
-
-43
-
Price
-
$13.94
Significant Holders of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) as of Q4 2023
182 filings reported holding VERV - Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2023.
Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) has 153 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 74.7M shares
of 89.6M outstanding shares and own 83.39% of the company stock.
Largest 10 shareholders include Alphabet Inc. (12.3M shares), ARK Investment Management LLC (7.03M shares), VANGUARD GROUP INC (5.47M shares), BlackRock Inc. (4.44M shares), FEDERATED HERMES, INC. (3.98M shares), STATE STREET CORP (3.87M shares), FMR LLC (3.44M shares), T. Rowe Price Investment Management, Inc. (3.17M shares), Casdin Capital, LLC (3.01M shares), and Nikko Asset Management Americas, Inc. (2.4M shares).
This table shows the top 153 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.